Breast MRI fibroglandular volume and parenchymal enhancement in BRCA1 and BRCA2 mutation carriers before and immediately after risk-reducing salpingo-oophorectomy

American Journal of Roentgenology

Volumn 204, Issue 3, 2015, Pages 669-673

  DeLeo, Michael J ^a   Domchek, Susan M ^a,b   Kontos, Despina ^a   Conant, Emily ^a   Chen, Jinbo ^a   Weinstein, Susan ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Breast cancer; Breast cancer risk reducing strategies; Breast MRI; High risk breast cancer screening

Indexed keywords

ADULT; AGED; ARTICLE; BACKGROUND PARENCHYMAL ENHANCEMENT; BREAST CANCER; CANCER DIAGNOSIS; CANCER RISK; CONTRAST ENHANCEMENT; FEMALE; FIBROGLANDULAR VOLUME; GENE MUTATION; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; RISK REDUCTION; SALPINGOOOPHORECTOMY; TUMOR SUPPRESSOR GENE; BREAST; COMPARATIVE STUDY; MIDDLE AGED; MUTATION; ORGAN SIZE; OVARIECTOMY; PATHOLOGY; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; RETROSPECTIVE STUDY; RISK; SALPINGECTOMY;

ADULT; AGED; BREAST; FEMALE; GENES, BRCA1; GENES, BRCA2; HETEROZYGOTE; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; MUTATION; ORGAN SIZE; OVARIECTOMY; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; RETROSPECTIVE STUDIES; RISK; SALPINGECTOMY;

EID: 84928421809     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.13.12146     Document Type: Article

References (26)

1. Foulkes WD. Inherited susceptibility to common cancers. N Engl J Med 2008; 359:2143-2153
2. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72:1117-1130
3. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003; 302:643-646
4. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 and BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010; 304:967-975
5. National Comprehensive Cancer Network (NCCN). Genetic/familial high risk assessment: breast and ovarian. NCCN website. www.nccn.org/professionals/physician-gls/pdf/genetics-screening.pdf. Published 2012. Accessed October 1, 2012
6. Shah P, Rosen M, Stopfer J, et al. Prospective study of breast MRI in BRCA1 and BRCA2 mutation carriers: effect of mutation status on cancer incidence. Breast Cancer Res Treat 2009; 118: 539-546
7. Warner E, Hill K, Causer P, et al. Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J Clin Oncol 2011; 29:1664-1669
8. McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006; 15:1159-1169
9. Wei J, Chan H, Helvie MA, et al. Correlation between mammographic density and volumetric f-broglandular tissue estimated on breast MR images. Med Phys 2004; 31:933-942
10. King V, Brooks JD, Bernstein JL, Reiner AS, Pike MC, Morris EA. Background parenchymal enhancement at breast MR imaging and breast cancer risk. Radiology 2011; 260:50-60
11. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33:159-174
12. Müller-Schimpfe M, Ohmenhaüser K, Stoll P, Dietz K, Claussen CD. Menstrual cycle and age: infuence on parenchymal contrast medium enhancement in MR imaging of the breast. Radiology 1997; 203:145-149
13. Kuhl CK, Seibert C, Sommer T, Kreft B, Gleseke J, Schild HH. Focal and diffuse contrast enhancing lesions in dynamic MRI of the breast in healthy volunteers (in German). Rofo 1995; 163:219-224
14. King V, Gu Y, Kaplan JB, Brooks JD, Pike MC, Morris EA. Impact of menopausal status on background parenchymal enhancement and fbroglandular tissue on breast MRI. Eur Radiol 2012; 22:2641-2647
15. Mousa NA, Eiada R, Crystal P, Nayot D, Casper RF. The effect of acute aromatase inhibition on breast parenchymal enhancement in magnetic resonance imaging: a prospective pilot clinical trial. Menopause 2012; 19:420-425
16. King V, Goldfarb SB, Brooks JD, et al. Effect of aromatase inhibitors on background parenchymal enhancement and amount of fbroglandular tissue at breast MR imaging. Radiology 2012; 264:670-678
17. King V, Kaplan J, Pike MC, et al. Impact of tamoxifen on amount of fbroglandular tissue, background parenchymal enhancement, and cysts on breast magnetic resonance imaging. Breast J 2012; 18:527-534
18. Price ER, Brooks JD, Watson EJ, Brennan SB, Comen EA, Morris EA. The impact of bilateral salpingo-oophorectomy on breast MRI background parenchymal enhancement and fbroglandular tissue. Eur Radiol 2014; 24:162-168
19. Mousa NA, Crystal P, Wolfman WL, Bedaiwy MA, Casper RF. Aromatase inhibitors and mam-mographic breast density in postmenopausal women receiving hormone therapy. Menopause 2008; 15:875-884
20. Smith J, Dilawari A, Ursin G, et al. A pilot study of letrozole for one year in women at enhanced risk of developing breast cancer: effects on mam-mographic breast density. Anticancer Res 2012; 32:1327-1331
21. Cigler T, Tu D, Yaffe MJ, et al. A randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammograph-ic breast density and other end organs in postmenopausal women. Breast Cancer Res Treat 2010; 120:427-435
22. Cigler T, Tu D, Yaffe MJ, et al. A randomized, placebo-controlled trial (NCIC CTG MAP2) examining the effects of exemestane on mammo-graphic breast density, bone density, markers of bone metabolism, and serum lipid levels in postmenopausal women. Breast Cancer Res Treat 2011; 126:453-461
23. Keller BM, Nathan DL, Wang Y, et al. Estimation of breast percent density in raw and processed full feld digital mammography images via adaptive fuzzy c-means clustering and support vector machine segmentation. Med Phys 2012; 39:4903-4917
24. Klifa C, Suzuki S, Aliu S, et al. Quantifcation of background enhancement in breast magnetic resonance imaging. J Magn Reson Imaging 2011; 33:1229-1234
25. Stoutjesdijk MJ, Futterer JJ, Boetes C, van Die LE, Jager G, Barentsz JO. Variability in the description of morphologic and contrast enhancement characteristics of breast lesions on magnetic resonance imaging. Invest Radiol 2005; 40:355-362
26. Redondo A, Comas M, Macia F, et al. Inter-and intraradiologist variability in the BI-R ADS assessment and breast density categories for screening mammograms. Br J Radiol 2012; 85:1465-1470